Product Description
Mechanisms of Action: B2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Menarini
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Osteoarthritis, Knee|Arthritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ALBATROSS-4 | P2 |
Temporarily not available |
Osteoarthritis, Knee |
2015-08-21 |
|
ALBATROSS-3 | P2 |
Completed |
Osteoarthritis, Knee |
2015-01-06 |
|
ALBATROSS-3 | P2 |
Completed |
Osteoarthritis, Knee |
2015-01-01 |
|
ALBATROSS-2 | P2 |
Completed |
Arthritis |
2013-02-01 |